Features associated with locoregional spread of papillary carcinoma correlate with diagnostic category in the Bethesda System
for Reporting Thyroid Cytopathology.
For more information on the Bethesda System
2001, go to www.
The Bethesda System
has two main components: a statement of adequacy and a descriptive diagnosis.
The Bethesda system
represents a substantial advance in cervical cytology reporting.
4) The Bethesda System
(TBS) for reporting cervicovaginal cytology describes atrophic vaginitis as "atrophy with inflammation," suggesting that the above criteria, with the addition of the presence of neutrophils, distinguishes atrophic vaginitis from atrophy.
The FDA approval was based on the results of a multi-site trial designed to evaluate the routine screening of ThinPrep Pap Test slides using the ThinPrep Imaging System compared to a manual review of ThinPrep Pap Test slides for all categories used for cytologic diagnosis (specimen adequacy and descriptive diagnosis) as defined by the Bethesda System
Although the Bethesda System
clearly states that such aspirates should be classified as nondiagnostic, (12) some pathologists prefer to classify such cases as negative under the assumption that the risk of malignancy in such a setting is lower than in other cases of nondiagnostic aspirates and the belief that reaspiration is unlikely to provide additional diagnostic information.
The Company believes that data from the clinical and clinical support studies of the ThinPrep Imaging System submitted to the FDA demonstrate that the use of the ThinPrep Imaging System to assist during routine primary screening of ThinPrep Pap Test slides for all cytologic interpretations, as defined by The Bethesda System
2001, is safe and effective for the detection of cervical abnormalities.
The Bethesda System
for Reporting Cervical/ Vaginal Cytologic Diagnoses: Definitions, Criteria and Explanatory Notes for Terminology and Specimen Adequacy.
This lab was a leader in implementing the Bethesda System
, Pap smear reporting and a system of quality assurance compliant with the Clinical Laboratory Improvement Amendments (CLIA) of 1988.
First, widespread implementation of the 2001 Bethesda System
(7) (TBS 2001) has occurred since its publication in 2002.
Cervicovaginal cytology surveys have been used since 1994 and have evaluated practices related to implementation of the Bethesda System
(TBS) terminology and reporting rates for interpretive categories used in Papanicolaou (Pap) testing.